Diabetes: FDA clears DexCom's mobile apps

The FDA clears DexCom's Share and Follow apps for diabetes patients using the company's G4 Platinum continuous glucose monitor, allowing patients and caregivers to track glucose levels on up to 5 mobile devices.

Dexcom Inc. (NSDQ:DXCM) won de novo approval from the FDA for the 1st U.S. app to wirelessly connect a patient's blood glucose monitor with up to 5 mobile devices.

DexCom Inc., Food & Drug Administration (FDA), Google Inc., Apple

News Well, De Novo Clearance, Diabetes, mHealth (Mobile Health), Regulatory/Compliance

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1CYjAOS